NOURESS Drug Patent Profile

Which patents cover Nouress, and when can generic versions of Nouress launch?

Nouress is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. There are nineteen patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in NOURESS is cysteine hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cysteine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Nouress

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 15, 2039. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (cysteine hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NOURESS

International Patents:	1
US Patents:	19
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	115
Patent Applications:	6,719
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOURESS
What excipients (inactive ingredients) are in NOURESS?	NOURESS excipients list
DailyMed Link:	NOURESS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NOURESS

Constraining patent/regulatory exclusivity:

10,493,051

NDA:

212535

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for NOURESS

NOURESS is protected by nineteen US patents.

This potential generic entry date is based on patent 10,493,051.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	10,543,186
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	10,905,713		Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	11,045,438		Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	11,510,942		Y
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	11,648,262		Y

International Patents for NOURESS

When does loss-of-exclusivity occur for NOURESS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NOURESS around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3070798	COMPOSITION DE CYSTEINE ET INJECTION (CYSTEINE COMPOSITION AND INJECTION)
Canada	3070798	COMPOSITION DE CYSTEINE ET INJECTION (CYSTEINE COMPOSITION AND INJECTION)

Supplementary Protection Certificates for NOURESS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0107734	93C0042	Belgium		PROD. NAME TETRAKIS (2-METHOXY-ISOBUTYL-ISONITRILE). CUIVRE (I) TETRAFLUOROBORATE, DIHYDRATE DE CHLORURE STANNEUX, CHLORHYDRATE DE L-CYSTEINE (MONOHYDRATE); REG NO/DATE 923 IS 3 F 12/ 19900924 ; FIRST REG CC NO DATE IE PA 200/9/1 19900817

Market Dynamics and Financial Trajectory for NOURESS

Last updated: April 28, 2026

What is NOURESS and where does it fit commercially?

NOURESS is a prescription pharmaceutical product positioned for use in the US. The product’s commercial trajectory is shaped by a small set of market drivers that determine uptake and revenue durability: channel placement, payor coverage, competition from comparable therapies, and regulatory/label constraints that affect prescriber behavior and refill demand.

Because a full, accurate market and financial trajectory requires non-public commercial datasets (e.g., paid claims, net sales by NDC, pharmacy benefit manager mix, and quarterly revenue by product line), a complete end-to-end view cannot be produced from the information provided in this prompt.

What market dynamics determine NOURESS adoption?

The adoption curve for a branded prescription drug typically depends on four levers that move quickly once coverage is established and slowly when clinical comfort builds:

1) Coverage and formulary placement

• PBM contracting and formulary access drive the initial “pull” into retail and specialty channels.
• Step edits, prior authorization, and quantity limits can materially delay volume ramp even after launch.

2) Channel strategy (retail vs specialty)

• Drugs with monitoring requirements, payer restrictions, or narrow patient populations often route to specialty channels.
• Specialty placement tends to concentrate volume and can flatten quarterly volatility if adherence programs exist.

3) Competitive set and label positioning

• Uptake depends on whether NOURESS displaces existing standard-of-care products or adds incremental patients.
• If alternatives have strong price concessions or better real-world persistence, NOURESS revenue typically ramps slower and plateaus earlier.

4) Safety and tolerability signals

• Post-launch safety events can change prescriber comfort and payor restrictions.
• Tolerability influences persistence, which is often the main driver of revenue durability after initial demand.

What does the financial trajectory likely look like over time?

In branded pharma, the most common revenue lifecycle patterns after launch are:

• Early ramp: Net sales rise as formulary coverage broadens, prescriber adoption spreads, and channel stocking normalizes.
• Mid-cycle growth or consolidation: Revenue either expands with new coverage lines and improved access or flattens under competitive pressure and tighter utilization management.
• Late-cycle pressure: Margin compression and volume erosion occur as competing products gain share and as gross-to-net components rise (rebates, copay programs, and chargebacks).

For NOURESS specifically, a precise financial trajectory requires product-level net sales history and gross-to-net breakdown. Those figures are not supplied in the prompt, so no accurate quarterly or annual forecast can be stated.

How do gross-to-net components shape net sales for NOURESS?

For most US branded pharmaceuticals, net sales reflect gross revenue minus a complex gross-to-net stack:

• Rebates and discounts (including Medicaid and managed care)
• Chargebacks through wholesaler and distribution channels
• Pharmacy benefit manager fees and administrative program costs
• Copay assistance costs (if applicable)
• Returns and shrink (depending on channel terms)

The key financial implication: two drugs with similar unit demand can show different net sales trajectories if rebate intensity and access requirements differ. Without NOURESS gross sales and rebate rates, the net-to-gross sensitivity cannot be quantified.

What role does pricing play in NOURESS profitability?

Branded pricing affects both top-line and net price, but the revenue story for NOURESS depends on how payors respond:

• Larger list price increases can raise gross revenue while net price remains constrained by rebates.
• If NOURESS has meaningful clinical or convenience advantages, it can sustain higher net pricing and improve gross-to-net efficiency.
• If competitive products offer better net pricing after concessions, NOURESS growth typically slows even if demand remains steady.

A quantified pricing and profitability analysis requires list price history, net price benchmarks, and payer contract details.

Where is NOURESS most exposed to risk?

The risk profile for branded products usually clusters in a few areas:

1. Formulary access shocks

   • Loss of preferred status, tighter prior authorization, or expanded step therapy can reverse volume trends quickly.

2. Competitive entry

   • New entrants with superior outcomes, lower net costs, or broader indication coverage can compress NOURESS share.

3. Utilization management tightening

   • PBMs often tighten criteria as product budgets mature, impacting persistence.

4. Safety or label changes

   • New warnings or restricted patient populations can reduce eligible population size.

5. Operational channel risk

   • Allocation, supply constraints, or distribution failures can interrupt monthly demand.

No NOURESS specific label changes, REMS updates, safety communications, or PBM coverage actions are included in the prompt, so no product-specific risk timeline can be built.

Can NOURESS revenue be benchmarked against peers?

Peer benchmarking requires:

• The drug’s indication(s)
• Route of administration and dosing frequency
• Target patient population size and diagnosis prevalence
• Competitive set and relative efficacy/safety profiles
• Real-world persistence rates
• Public net sales for comparators

None of these details for NOURESS are provided here, so peer benchmarking cannot be performed without generating non-factual estimates.

What financial milestones matter most to investors?

In practice, investors track a small set of milestones that map directly to revenue:

• Launch quarter coverage (number of live contracts; timing of preferred tier placement)
• Quarterly net sales stability (gross-to-net changes, buy-in cycles, chargebacks)
• Prescription volume trend (TRx growth and persistence)
• Market share change (displacement versus additive demand)
• Indication expansion cadence (if any)
• Manufacturing/supply continuity (no revenue loss from allocation)

For NOURESS, those milestones are not included in the prompt, so a factual milestone timeline cannot be constructed.

Key Takeaways

• NOURESS’ market and financial path depends primarily on formulary access, channel strategy, competitive displacement, and persistence driven by tolerability and payer utilization controls.
• A complete, accurate market size trajectory and financial forecast for NOURESS cannot be produced from the information provided in this prompt.
• Any investable conclusions require product-level net sales, gross-to-net components, and coverage/claims data by quarter, none of which are included here.

FAQs

What drives NOURESS volume growth after launch?

Formulary access, prior authorization easing, preferred tier placement, and patient persistence.

What usually pressures net sales for branded drugs like NOURESS?

Gross-to-net inflation from rebates, chargebacks, and tighter utilization management, plus competitive net pricing.

How does specialty versus retail distribution change NOURESS revenue volatility?

Specialty channels often concentrate demand through tighter payer routing, which can reduce volatility if adherence support exists; retail can show more variability based on stocking and channel terms.

What competitive events most affect NOURESS share?

New product launches with stronger clinical differentiation, improved net pricing, or broader indication coverage.

Which regulatory factors most influence NOURESS prescribing?

Label restrictions, safety communications, and any changes that alter eligible populations or require additional monitoring.

---

References

[1] No sources were provided in the prompt.